Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study

Ítems similars

• Inverse Correlation between Serum Levels of Selenoprotein P and Adiponectin in Patients with Type 2 Diabetes
  per: Misu, Hirofumi, et al.
  Publicat: (2012)
• Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease
  per: Kato, Ken-ichiro, et al.
  Publicat: (2015)
• Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
  per: Takeshita, Yumie, et al.
  Publicat: (2015)
• Ectopic Fat Accumulation and Distant Organ-Specific Insulin Resistance in Japanese People with Nonalcoholic Fatty Liver Disease
  per: Kato, Ken-ichiro, et al.
  Publicat: (2014)
• Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes
  per: Kanamori, Takehiro, et al.
  Publicat: (2018)